Focused On-demand Library for SLAM family member 6

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q96DU3

UPID:

SLAF6_HUMAN

Alternative names:

Activating NK receptor; NK-T-B-antigen

Alternative UPACC:

Q96DU3; A6NMW2; B2R8X8; Q14CF0; Q5TAS4; Q5TAS6; Q5TAT3; Q96DV0

Background:

SLAM family member 6, also known as Activating NK receptor or NK-T-B-antigen, plays a pivotal role in immune regulation. It modulates the activation and differentiation of various immune cells, contributing to both innate and adaptive immune responses. This protein's function is influenced by the presence of adapter proteins SH2D1A/SAP and SH2D1B/EAT-2, which control its signaling pathways. It is particularly crucial in natural killer (NK) cell activation, T-cell differentiation into Th17 phenotype, and the regulation of germinal center formation.

Therapeutic significance:

Understanding the role of SLAM family member 6 could open doors to potential therapeutic strategies. Its involvement in key immune processes suggests its potential as a target in modulating immune responses, offering avenues for the development of treatments for immune-related disorders.